Prosight Management, LP - Q3 2020 holdings

$210 Million is the total value of Prosight Management, LP's 47 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 59.6% .

 Value Shares↓ Weighting
ALXN BuyALEXION PHARMACEUTICALS INC$13,251,000
+31.2%
115,800
+28.7%
6.30%
+45.4%
ARNA SellARENA PHARMACEUTICALS INC$12,195,000
-14.7%
163,057
-28.2%
5.80%
-5.5%
BMY BuyBRISTOL-MYERS SQUIBB CO$11,184,000
+61.2%
185,500
+57.2%
5.32%
+78.6%
RETA BuyREATA PHARMACEUTICALS INCcl a$11,160,000
-12.9%
114,554
+39.5%
5.31%
-3.5%
CUE BuyCUE BIOPHARMA INC$10,685,000
+40.5%
709,936
+128.8%
5.08%
+55.7%
BAX BuyBAXTER INTL INC$9,811,000
+168.1%
122,000
+187.1%
4.67%
+197.0%
CHNG SellCHANGE HEALTHCARE INC$9,057,000
-2.6%
624,200
-24.8%
4.31%
+7.9%
AUPH BuyAURINIA PHARMACEUTICALS INC$8,764,000
+486.2%
595,000
+546.7%
4.17%
+549.2%
ALDX SellALDEYRA THERAPEUTICS INC$8,092,000
+19.8%
1,092,000
-32.6%
3.85%
+32.7%
CI BuyCIGNA CORP NEW$7,962,000
+10.2%
47,000
+22.1%
3.79%
+22.1%
EHC BuyENCOMPASS HEALTH CORP$7,013,000
+244.3%
107,921
+228.0%
3.34%
+281.7%
CNC SellCENTENE CORP DEL$6,879,000
-32.2%
117,935
-26.2%
3.27%
-24.9%
BuyAPTOSE BIOSCIENCES INC$6,835,000
+38.3%
1,139,094
+45.5%
3.25%
+53.3%
ZBH SellZIMMER BIOMET HOLDINGS INC$6,616,000
-19.1%
48,600
-29.1%
3.15%
-10.3%
QURE BuyUNIQURE NV$6,313,000
-2.1%
171,429
+19.8%
3.00%
+8.5%
PRTA NewPROTHENA CORP PLC$5,447,000545,195
+100.0%
2.59%
MTCR NewMETACRINE INC$5,297,000518,796
+100.0%
2.52%
MGTX SellMEIRAGTX HLDGS PLC$5,178,000
-20.5%
391,099
-24.8%
2.46%
-11.8%
ACIU SellAC IMMUNE SA$4,505,000
-43.1%
923,117
-21.6%
2.14%
-37.0%
ALBO SellALBIREO PHARMA INC$4,088,000
-22.4%
122,500
-38.4%
1.94%
-14.0%
IOVA SellIOVANCE BIOTHERAPEUTICS INC$3,970,000
-32.7%
120,606
-43.9%
1.89%
-25.5%
NewALEXION PHARMACEUTICALS INCcall$3,891,00034,000
+100.0%
1.85%
TBIO BuyTRANSLATE BIO INC$3,839,000
+139.3%
282,100
+215.2%
1.83%
+165.0%
SellISHARES TRput$3,595,000
-87.1%
24,000
-87.7%
1.71%
-85.7%
CLLS SellCELLECTIS S Aspon ads$3,426,000
-30.4%
185,180
-33.0%
1.63%
-22.9%
KURA SellKURA ONCOLOGY INC$3,290,000
-70.5%
107,367
-84.3%
1.56%
-67.3%
ZGNX BuyZOGENIX INC$3,243,000
-18.0%
180,924
+23.6%
1.54%
-9.1%
ORGO BuyORGANOGENESIS HLDGS INC$2,598,000
+26.3%
676,553
+26.3%
1.24%
+40.0%
CARA BuyCARA THERAPEUTICS INC$2,222,000
+49.4%
174,644
+100.8%
1.06%
+65.7%
AMRX NewAMNEAL PHARMACEUTICALS INC$1,989,000512,659
+100.0%
0.95%
ONEM New1LIFE HEALTHCARE INC$1,865,00065,778
+100.0%
0.89%
KZR NewKEZAR LIFE SCIENCES INC$1,771,000365,981
+100.0%
0.84%
MGTA BuyMAGENTA THERAPEUTICS INC$1,661,000
+31.2%
244,252
+44.9%
0.79%
+45.5%
QDEL NewQUIDEL CORP$1,645,0007,500
+100.0%
0.78%
ESTA SellESTABLISHMENT LABS HLDGS INC$1,594,000
-32.9%
86,042
-32.3%
0.76%
-25.7%
CBIO BuyCATALYST BIOSCIENCES INC$1,297,000
-10.9%
301,678
+21.6%
0.62%
-1.3%
BTAI NewBIOXCEL THERAPEUTICS INC$1,292,00029,800
+100.0%
0.62%
ADMA SellADMA BIOLOGICS INC$1,280,000
-66.4%
535,324
-58.8%
0.61%
-62.7%
KRTX NewKARUNA THERAPEUTICS INC$1,224,00015,826
+100.0%
0.58%
IMTX NewIMMATICS N.V$1,204,000113,460
+100.0%
0.57%
NLTX NewNEOLEUKIN THERAPEUTICS INC$797,00066,376
+100.0%
0.38%
EVFM SellEVOFEM BIOSCIENCES INC$590,000
-49.5%
250,000
-39.4%
0.28%
-43.9%
APEN SellAPOLLO ENDOSURGERY INC$469,000
-24.5%
277,590
-26.9%
0.22%
-16.5%
KIDS NewORTHOPEDIATRICS CORP$386,0008,399
+100.0%
0.18%
MITO SellSTEALTH BIOTHERAPEUTICS CORPsponsored ads$346,000
-35.1%
256,044
-12.1%
0.16%
-27.9%
BEAT SellBIOTELEMETRY INC$274,000
-75.5%
6,000
-75.7%
0.13%
-72.9%
NewREATA PHARMACEUTICALS INCcall$156,0001,600
+100.0%
0.07%
ExitEVOLUS INCcall$0-37,400
-100.0%
-0.08%
ExitZOGENIX INCput$0-8,200
-100.0%
-0.10%
Exit1LIFE HEALTHCARE INCput$0-8,000
-100.0%
-0.12%
MGLN ExitMAGELLAN HEALTH INC$0-5,200
-100.0%
-0.16%
LHCG ExitLHC GROUP INC$0-4,509
-100.0%
-0.34%
XERS ExitXERIS PHARMACEUTICALS INC$0-419,469
-100.0%
-0.48%
PRSC ExitPROVIDENCE SVC CORP$0-14,923
-100.0%
-0.51%
NEO ExitNEOGENOMICS INC$0-38,819
-100.0%
-0.52%
AMN ExitAMN HEALTHCARE SVCS INC$0-26,851
-100.0%
-0.52%
EOLS ExitEVOLUS INC$0-281,541
-100.0%
-0.64%
TPTX ExitTURNING POINT THERAPEUTICS I$0-25,602
-100.0%
-0.71%
UTHR ExitUNITED THERAPEUTICS CORP DEL$0-15,000
-100.0%
-0.78%
IMVT ExitIMMUNOVANT INC$0-95,500
-100.0%
-1.00%
PSNL ExitPERSONALIS INC$0-188,750
-100.0%
-1.05%
PCRX ExitPACIRA BIOSCIENCES$0-55,000
-100.0%
-1.24%
VCEL ExitVERICEL CORP$0-209,897
-100.0%
-1.24%
ExitBRISTOL-MYERS SQUIBB COcall$0-50,000
-100.0%
-1.26%
ARWR ExitARROWHEAD PHARMACEUTICALS IN$0-114,100
-100.0%
-2.12%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2020-11-13
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ALDEYRA THERAPEUTICS INC19Q2 20236.2%
ALBIREO PHARMA INC18Q4 20229.2%
MEIRAGTX HOLDINGS PLC18Q3 20236.3%
KEZAR LIFE SCIENCES INC17Q3 20238.2%
ARENA PHARMACEUTICALS INC16Q4 20218.2%
IOVANCE BIOTHERAPEUTICS INC16Q1 20227.7%
CENTENE CORP DEL16Q3 20235.3%
CUE BIOPHARMA INC14Q1 20235.6%
PROTHENA CORP PLC13Q3 202313.6%
ZIMMER BIOMET HOLDINGS INC13Q3 20219.8%

View Prosight Management, LP's complete holdings history.

Latest significant ownerships (13-D/G)
Prosight Management, LP Q3 2020 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
EXICURE, INC.February 14, 20222,426,5082.2%
Aldeyra Therapeutics, Inc.February 12, 2021908,4882.3%
Teligent, Inc.February 14, 20201,484,5272.8%
Cidara Therapeutics, Inc.February 14, 2019245,7640.9%
Eiger BioPharmaceuticals, Inc.Sold outFebruary 14, 201900.0%
Millendo Therapeutics, Inc.February 14, 2019256,7392.0%
OvaScience, Inc.October 26, 20181,991,1005.6%
CHIMERIX INCFebruary 13, 20181,478,5193.1%
Harvard Apparatus Regenerative Technology, Inc.February 12, 2016184,3601.4%

View Prosight Management, LP's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-02-14
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G2024-01-02
13F-HR2023-11-14
SC 13G2023-09-01

View Prosight Management, LP's complete filings history.

Compare quarters

Export Prosight Management, LP's holdings